Efficacy and tolerability of a topical skin-lightening cosmetic product combination on facial dyspigmentation compared with 4% hydroquinone

Not Applicable

Completed

• Conditions: Mild to moderate facial dyspigmentation due to melasma, but otherwise healthy skin; Skin and Connective Tissue Diseases

• Registration Number: ISRCTN33310512
• Lead Sponsor: ISISPHARMA

Brief Summary

2019 results in https://www.ncbi.nlm.nih.gov/pubmed/31858658 (added 19/02/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-05-31
• Study Start: 2019-01-30
• Last Update Posted: 3 March 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

1. Women or men
2. Aged between 18 and 60 years
3. Skin phototype IV-V
4. Presenting facial dyspigmentation due to melasma as determined by Wood’s light examination

Exclusion Criteria

1. Pregnant or nursing women or women planning to get pregnant during the study
2. Subjects with a cutaneous pathology on the study zone (eczema)
3. Subjects having undergone surgery under general anaesthesia within the previous month
4. Individuals who have been excessively exposed to sunlight or UV-rays within the previous month
5. Subjects having used topical or systemic treatment during the previous weeks liable to interfere with the assessment of the cutaneous acceptability of the study product

Study & Design

• Study Type: Interventional
• Study Design: Not specified